Cargando…

30-Day Outcomes after Surgical or Transapical Aortic Valve Replacement in Symptomatic Aortic Regurgitation

Background: We aimed to analyze the short-term clinical outcomes of transapical aortic valve replacement (TA-TAVR) compared with surgical aortic valve replacement (SAVR) in symptomatic aortic regurgitation (AR) patients to draw preliminary conclusions about the advantages and disadvantages of TA-TAV...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Minjian, Hong, Ze, Liu, Xianbao, Zhu, Xian, Wang, Jianan, Dong, Aiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323817/
https://www.ncbi.nlm.nih.gov/pubmed/35877586
http://dx.doi.org/10.3390/jcdd9070224
_version_ 1784756647252459520
author Kong, Minjian
Hong, Ze
Liu, Xianbao
Zhu, Xian
Wang, Jianan
Dong, Aiqiang
author_facet Kong, Minjian
Hong, Ze
Liu, Xianbao
Zhu, Xian
Wang, Jianan
Dong, Aiqiang
author_sort Kong, Minjian
collection PubMed
description Background: We aimed to analyze the short-term clinical outcomes of transapical aortic valve replacement (TA-TAVR) compared with surgical aortic valve replacement (SAVR) in symptomatic aortic regurgitation (AR) patients to draw preliminary conclusions about the advantages and disadvantages of TA-TAVR compared with SAVR and to provide evidence for future use of TA-TAVR in AR patients. Method: From September 2016 to September 2021, 69 patients undergoing TA-TAVR with J-valve implantation and 42 patients undergoing SAVR at the Second Hospital of Zhejiang University School of Medicine were analyzed for clinical data and 30-day follow-up outcomes to analyze and compare the differences in clinical endpoints between the two procedures. Results: At 30-day follow-up, there were no significant differences in mortality or neurological events between the two groups before and after the PSM. In secondary endpoints there were significant differences between the pre-match TAVR and SAVR groups, such as the incidence of paravalvular leaks (33.8% vs. 4.8%, p < 0.05), which also remained after the PSM (37.5% vs. 0, p < 0.05). In addition, the incidence of major bleeding was 7.4% in the TAVR group and 26.2% in the SAVR group before matching (p < 0.05). After matching, the statistical difference still remained. In longitudinal comparison, significant improvements in postoperative cardiac ultrasound indices and NYHA classification occurred in both groups. Conclusion: The TA-TAVR approach is safe and reliable, with similar clinical efficacy to SAVR, and has advantages in bleeding rate and speed of recovery.
format Online
Article
Text
id pubmed-9323817
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93238172022-07-27 30-Day Outcomes after Surgical or Transapical Aortic Valve Replacement in Symptomatic Aortic Regurgitation Kong, Minjian Hong, Ze Liu, Xianbao Zhu, Xian Wang, Jianan Dong, Aiqiang J Cardiovasc Dev Dis Article Background: We aimed to analyze the short-term clinical outcomes of transapical aortic valve replacement (TA-TAVR) compared with surgical aortic valve replacement (SAVR) in symptomatic aortic regurgitation (AR) patients to draw preliminary conclusions about the advantages and disadvantages of TA-TAVR compared with SAVR and to provide evidence for future use of TA-TAVR in AR patients. Method: From September 2016 to September 2021, 69 patients undergoing TA-TAVR with J-valve implantation and 42 patients undergoing SAVR at the Second Hospital of Zhejiang University School of Medicine were analyzed for clinical data and 30-day follow-up outcomes to analyze and compare the differences in clinical endpoints between the two procedures. Results: At 30-day follow-up, there were no significant differences in mortality or neurological events between the two groups before and after the PSM. In secondary endpoints there were significant differences between the pre-match TAVR and SAVR groups, such as the incidence of paravalvular leaks (33.8% vs. 4.8%, p < 0.05), which also remained after the PSM (37.5% vs. 0, p < 0.05). In addition, the incidence of major bleeding was 7.4% in the TAVR group and 26.2% in the SAVR group before matching (p < 0.05). After matching, the statistical difference still remained. In longitudinal comparison, significant improvements in postoperative cardiac ultrasound indices and NYHA classification occurred in both groups. Conclusion: The TA-TAVR approach is safe and reliable, with similar clinical efficacy to SAVR, and has advantages in bleeding rate and speed of recovery. MDPI 2022-07-14 /pmc/articles/PMC9323817/ /pubmed/35877586 http://dx.doi.org/10.3390/jcdd9070224 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kong, Minjian
Hong, Ze
Liu, Xianbao
Zhu, Xian
Wang, Jianan
Dong, Aiqiang
30-Day Outcomes after Surgical or Transapical Aortic Valve Replacement in Symptomatic Aortic Regurgitation
title 30-Day Outcomes after Surgical or Transapical Aortic Valve Replacement in Symptomatic Aortic Regurgitation
title_full 30-Day Outcomes after Surgical or Transapical Aortic Valve Replacement in Symptomatic Aortic Regurgitation
title_fullStr 30-Day Outcomes after Surgical or Transapical Aortic Valve Replacement in Symptomatic Aortic Regurgitation
title_full_unstemmed 30-Day Outcomes after Surgical or Transapical Aortic Valve Replacement in Symptomatic Aortic Regurgitation
title_short 30-Day Outcomes after Surgical or Transapical Aortic Valve Replacement in Symptomatic Aortic Regurgitation
title_sort 30-day outcomes after surgical or transapical aortic valve replacement in symptomatic aortic regurgitation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323817/
https://www.ncbi.nlm.nih.gov/pubmed/35877586
http://dx.doi.org/10.3390/jcdd9070224
work_keys_str_mv AT kongminjian 30dayoutcomesaftersurgicalortransapicalaorticvalvereplacementinsymptomaticaorticregurgitation
AT hongze 30dayoutcomesaftersurgicalortransapicalaorticvalvereplacementinsymptomaticaorticregurgitation
AT liuxianbao 30dayoutcomesaftersurgicalortransapicalaorticvalvereplacementinsymptomaticaorticregurgitation
AT zhuxian 30dayoutcomesaftersurgicalortransapicalaorticvalvereplacementinsymptomaticaorticregurgitation
AT wangjianan 30dayoutcomesaftersurgicalortransapicalaorticvalvereplacementinsymptomaticaorticregurgitation
AT dongaiqiang 30dayoutcomesaftersurgicalortransapicalaorticvalvereplacementinsymptomaticaorticregurgitation